Home » Stocks » CNS Pharmaceuticals

CNS Pharmaceuticals, Inc. (CNSP)

Stock Price: $2.02 USD 0.15 (8.02%)
Updated Jul 16, 2020 1:54 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 33.23M
Revenue (ttm) n/a
Net Income (ttm) -5.63M
Shares Out 16.45M
EPS (ttm) -0.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 16, 2020
Last Price $2.02
Previous Close $1.87
Change ($) 0.15
Change (%) 8.02%
Day's Open 1.95
Day's Range 1.85 - 2.05
Day's Volume 49,529
52-Week Range 1.26 - 5.69

More Stats

Market Cap 33.23M
Enterprise Value 27.85M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 16.45M
Float 6.49M
EPS (basic) -0.38
EPS (diluted) -0.64
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 100,624
Short Ratio 0.88
Short % of Float 1.57%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 5.24
Revenue n/a
Operating Income -5.61M
Net Income -5.63M
Free Cash Flow n/a
Net Cash 5.38M
Net Cash / Share 0.33
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -103.60%
ROE -218.44%
ROIC 9,065.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

Current: 2.02
Target: 11.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-3.83-0.88
Net Income-3.88-7.39
Shares Outstanding13.6510.51
Earnings Per Share-0.28-0.70
Operating Cash Flow-3.55-0.72
Capital Expenditures-0.02-
Free Cash Flow-3.57-0.72
Cash & Equivalents7.240.56
Total Debt-0.32
Net Cash / Debt7.240.24
Book Value7.60-0.55
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name CNS Pharmaceuticals, Inc.
Country United States
Employees 3
CEO John M. Climaco

Stock Information

Ticker Symbol CNSP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CNSP


CNS Pharmaceuticals, Inc., a preclinical stage pharmaceutical company, focuses on the development of anti-cancer drug candidates for the treatment of primary and metastatic brain, and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma. It has a development agreement with WPD Pharmaceuticals Inc. for the development of several preclinical drug candidates including WP1122, which will be tested on a range of viruses, including the coronavirus SARS-CoV-2. CNS Pharmaceuticals, Inc. was founded in 2017 and is based in Houston, Texas.